Latest Breaking News On - Company masterkey - Page 4 : comparemela.com

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and.

United statesBlack diamondUnited kingdomMario corsoPatrick wenSergey yurasovIvy brain tumor centerDiamond therapeutics incCompany masterkeyExchange commissionInternational conference on molecularOncology at dana farber cancer instituteDiamond therapeuticsDana farber cancerMolecular targetsResponse assessment

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023.

United statesUnited kingdomBlack diamondMario corsoMark vellecaJulie seidelDrug administrationExchange commissionIvy brain tumor centerDevelopment expensesCompany masterkeyInternational conference on molecularDiamond therapeutics incMolecular targetsDiamond therapeuticsChief executive officer

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three.

United statesUnited kingdomMario corsoHelena yuJulie seidelSergey yurasovDiamond therapeutics incInternational conference on molecularMemorial sloan kettering cancer centerExchange commissionCompany masterkeyGlobenewswire incDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitor

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMario corsoJulie seidelHelena yuSergey yurasovCompany masterkeyInternational conference on molecularPhysician at memorial sloan kettering cancer centerDiamond therapeutics incExchange commissionDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitorNon small cell lung cancer

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJulie seidelSergey yurasovMario corsoHelena yuExchange commissionPhysician at memorial sloan kettering cancer centerCompany masterkeyDiamond therapeutics incInternational conference on molecularDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitorNon small cell lung cancer